Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
NCT04146298Phase 2Recruiting
- Sponsor
- Changhai Hospital
- Start
- Oct 2021
- Primary completion
- Jun 2027
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Mutant KRAS G12V-specific TCR transduced autologous T cells in pancreatic cancer (PC), sponsored by Changhai Hospital. Primary endpoints: Treatment-related adverse events at 18 months and Objective response rate up to 18 months. Started Oct 2021; status: recruiting.
02
Drugs
Mutant KRAS G12V-specific TCR transduced autologous T cells
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04146298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04146298.